PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial, page-352

I could see many post from @Peeteepoo and others about MPL could succeed to treat Alzheimer's Dementia, however I do not deny that's still a possibility but I disagree that at current stage PAA should not embark on that path and deviate from its primary target to treat MND as MPL has already shown a great deal confidence with efficacy an effectiveness (58% improvement). Once we have enough creditability with MPL, we can certainly also trial Alzheimers and Dementia. What the new board/management need to focus (IMO) are:

• First thing first, get all necessary members of BoD asap with experience and credibility. A Small but effective BoD add more value to shareholders (as I have seen with NEU and DXB). [A mixture of SME, finance background and also who have succeeded in getting FDA approval will add more credit, not sure if MT will be still interested. We already have a wold class technical advisory board of neurologist/SME, head of manufacturing and head of operations with medical background]
• Secure confidence of shareholder and new investors by releasing updated ALSFRS-R and Survival Analysis to be generated by Berry Consultants as you have promised to update this data in coming weeks (from last Investor presntation)
• The recent FDA ODD designation to MPL was wasted with selfish outgoing board, I suggest to take proactive approach to advertise superiority of of MPL over already available drugs (QALSODY and RILUTEK) with evidence of data.
• Provide shareholders a time line with clear targets and keep the promise intact as market do not like uncertainty. I understand there is a lot more things happening in the background with recent BoD reshuffle but give us a chance to trust you that you have made a paradigm shift to outgoing board.

I'll be keep watching how things unfolds in next few weeks, months and beyond. I still trust science and believe on success of MPL to treat unmet need of MND.

The release of survival analysis from Barry consulting next week will change momentum in SP appreciation.